Anixa Biosciences (ANIX) Total Liabilities (2010 - 2026)

Anixa Biosciences (ANIX) has reported Total Liabilities for 17 consecutive years, with $1.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Liabilities fell 20.76% year-over-year to $1.6 million; the trailing twelve-month figure through Apr 2026 stood at $1.6 million (down 20.76% YoY), and the FY2025 full-year result was $2.1 million, down 21.2% from the prior year.
• Total Liabilities slipped to $1.6 million in Q2 2026 per ANIX's latest filing, from $2.1 million in the prior quarter.
• Across five years, Total Liabilities topped out at $2.7 million in Q4 2024 and bottomed at $1.4 million in Q2 2022.
• Historically, Total Liabilities has averaged $2.0 million across 5 years, with a median of $2.0 million in 2022.
• The sharpest annual moves came in 2022 and 2023: Total Liabilities surged 48.46% in 2022, then sank 30.16% in 2023.
• Over 5 years, Total Liabilities stood at $2.2 million in 2022, then decreased by 2.76% to $2.2 million in 2023, then climbed by 25.66% to $2.7 million in 2024, then slipped by 21.2% to $2.1 million in 2025, then decreased by 22.96% to $1.6 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $1.6 million, $2.1 million, and $2.2 million for Q2 2026, Q4 2025, and Q3 2025 respectively.